Fund I's latest new investment, in cell therapy company BOOST Pharma.
BOOST Pharma is a clinical-stage biotech company developing BT-101 for children with severe Osteogenesis Imperfecta (OI)
BOOST Pharma is a clinical-stage biotech company developing BT-101 for children with severe Osteogenesis Imperfecta (OI). The company builds on scientific work originating at Karolinska Institutet in Sweden and operates from Copenhagen, Denmark.